Janssen Korea, which has decided to operate its Hyangnam plant by this year, will also import the antifungal drug "Sporanox (Itraconazole)." As a result, co-marketing with Yuhan is expected to end.
According to industries on the 21st, Janssen's Sporanox Cap is going to convert its imports by changing its license at the end of June. Sporanox has long led the market as an oral antifungal drug licensed in 1989.

However, other ingredients such as fluconazole have advanced, and other products have recently been in the spotlight, recording ₩3.4 billion in sales based on UBIST last year. In 2008, Janssen and Yuhan signed a co-marketing contract, and Janssen decided to supply the same ingredient of